JO
CTKB icon

John Overdeck’s Cytek Biosciences CTKB Stock Holding History

John Overdeck’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$745K Buy
168,218
+142,618
+557% +$609K ﹤0.01% 3849
2026
Q1 		$112K Sell
25,600
-4,432
-15% -$20.9K ﹤0.01% 4374
2025
Q4 		$152K Sell
30,032
-145,727
-83% -$677K ﹤0.01% 3804
2025
Q3 		$610K Buy
+175,759
New +$660K ﹤0.01% 2888
2024
Q2 		– Sell
-13,211
Closed -$88.6K – 3081
2024
Q1 		$88.6K Buy
+13,211
New +$104K ﹤0.01% 2843
2022
Q2 		– Sell
-524,421
Closed -$5.65M – 2584
2022
Q1 		$5.65M Buy
+524,421
New +$7.08M 0.02% 867

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's CTKB Position: Q2 2026 in Review

John Overdeck increased its Cytek Biosciences (CTKB) stake by 557% in Q2 2026, buying an estimated $609K and bringing the position to 168,218 shares worth $745K. The position accounts for ﹤0.01% of the portfolio, ranked #3849.

John Overdeck first reported a position in CTKB in Q1 2022 and has held it in 6 quarters since. The position peaked at $5.65M in Q1 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • John Overdeck held 168,218 shares of Cytek Biosciences worth $745K as of Q2 2026.
  • John Overdeck bought 142,618 Cytek Biosciences shares in Q2 2026, an estimated $609K.
  • Cytek Biosciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3849 holding.
  • John Overdeck first reported a position in Cytek Biosciences in Q1 2022 and has held it in 6 quarters since.
  • John Overdeck's Cytek Biosciences position peaked at $5.65M in Q1 2022.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.